Shares of FAMEGLOW (HKEX: 03774) experienced a significant rise, climbing more than 14% during the trading session. At the time of writing, the stock was up 12.95% to HK$18.4, with a trading turnover of HK$9.9648 million.

Catalyst for the Move

A key development for the company occurred in late June, when it successfully transitioned its listing from the Growth Enterprise Market (GEM) to the Main Board of the Hong Kong Stock Exchange. This move is anticipated to enhance trading liquidity for its shares and provide greater flexibility for the company's long-term strategic development.

Company Background

FAMEGLOW is a Hong Kong-based medical aesthetic services provider. To date, the company operates a network of 16 medical aesthetic centers. Its brand, perFACE, recently received significant recognition, winning the Hydrafacial™ "Best Service Provider" award for the Asia-Pacific region and solidifying its position as the top-selling brand in Hong Kong.

Strategic Direction

Looking ahead, the company is strategically pivoting its focus towards the emerging field of "AI + high-end biotechnology skincare." In October 2025, FAMEGLOW established a joint venture with partners including a Japanese pharmaceutical company and a Singaporean commercial biotech firm. This joint venture is concentrated on the research, development, and sales of anti-aging products and solutions.

The joint venture has already launched its precision anti-aging brand, "素肌源创," which aims to provide customers with comprehensive, holistic anti-aging solutions.